Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DLN4R8
|
|||
| Drug Name |
Minjuvi
|
|||
| Synonyms |
Tafasitamab
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-10: C81-C86; ICD-9: 202] | Phase 2 | [1] | |
| Company |
MorphoSys
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-lymphocyte surface antigen B4 (CD19) | Target Info | . | [2] |
| KEGG Pathway | PI3K-Akt signaling pathway | |||
| Hematopoietic cell lineage | ||||
| B cell receptor signaling pathway | ||||
| Epstein-Barr virus infection | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | IL-7 Signaling Pathway | |||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | PIP3 activates AKT signaling | |||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| Constitutive Signaling by Aberrant PI3K in Cancer | ||||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
| WikiPathways | Human Complement System | |||
| Signaling by the B Cell Receptor (BCR) | ||||
| PIP3 activates AKT signaling | ||||
| B Cell Receptor Signaling Pathway | ||||
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05626322) A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION. U.S.National Institutes of Health. | |||
| REF 2 | Tafasitamab: First Approval. Drugs. 2020 Nov;80(16):1731-1737. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.